Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer

MET exon 14 (METex14) skipping drives tumor growth in 3%–4% of non-small cell lung cancers (NSCLCs) (Hong et al., 2021). In these tumors, aberrant MET messenger RNA splicing causes production of an abnormal MET receptor with enhanced stability (Hong et al., 2021). This increases MET signaling, which promotes cancer cell proliferation and survival.